InflaRx: IDMC Recommends To Stop Vilobelimab Phase 3 Trial In Pyoderma Gangrenosum Due To Futility

InflaRx N.V. announced that the Independent Data Monitoring Committee recommended halting the Phase 3 trial of vilobelimab for pyoderma gangrenosum (PG) due to futility, leading the company to discontinue its development for this indication and prioritize INF904. The company anticipates Phase 2a data readouts for INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) this summer and will focus on extending its cash runway. Vilobelimab remains available in the U.S. under Emergency Use Authorization for COVID-19 and has marketing authorization in the EU for SARS-CoV-2-induced ARDS.

Analysis

InflaRx N.V. faces a significant clinical setback following the Independent Data Monitoring Committee's (IDMC) recommendation to halt its Phase 3 trial of vilobelimab for pyoderma gangrenosum (PG) due to futility, an assessment based on an unblinded interim analysis of the first 30 enrolled patients. Consequently, InflaRx will cease further development of vilobelimab for the PG indication, a development that aligns with the strongly negative sentiment score of -0.7 and a per-ticker sentiment of -0.8 for IFRX. The company is now strategically redirecting its focus and resources towards its oral C5aR inhibitor, INF904, with crucial Phase 2a data readouts in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) anticipated this summer. In response to the trial failure, InflaRx is also actively considering additional cost-saving measures to extend its cash runway, a critical move for funding its revised priorities. While vilobelimab (GOHIBIC) maintains its Emergency Use Authorization in the U.S. for specific severe COVID-19 cases and a marketing authorization under exceptional circumstances in the EU for SARS-CoV-2-induced ARDS, these niche applications are unlikely to offset the impact of the PG program's discontinuation, placing heightened importance on the success of INF904.

Key Decisions for Investors

• Closely scrutinize the upcoming Phase 2a data readouts for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa this summer, as these results are now paramount for InflaRx's future valuation following the vilobelimab PG trial termination.
• Assess InflaRx's announced measures for cost savings and resource redirection, as effective cash runway extension is critical to support the prioritized development of INF904 and navigate the financial impact of the PG program's discontinuation.
• Re-evaluate investment theses to reflect the removal of vilobelimab's PG indication from the pipeline, acknowledging the increased reliance on INF904 and the limited commercial scope of vilobelimab's existing COVID-19 authorizations.